- Home
- COGT vs SBLK Comparison
COGT vs SBLK Comparison
Compare COGT & SBLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- SBLK
- Stock Information
- Founded
- COGT 2014
- SBLK 2006
- Country
- COGT United States
- SBLK Greece
- Employees
- COGT N/A
- SBLK N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- SBLK Marine Transportation
- Sector
- COGT Health Care
- SBLK Consumer Discretionary
- Exchange
- COGT Nasdaq
- SBLK Nasdaq
- Market Cap
- COGT 2.3B
- SBLK 2.1B
- IPO Year
- COGT 2018
- SBLK N/A
- Fundamental
- Price
- COGT $16.30
- SBLK $18.82
- Analyst Decision
- COGT Strong Buy
- SBLK Buy
- Analyst Count
- COGT 12
- SBLK 2
- Target Price
- COGT $22.00
- SBLK $21.50
- AVG Volume (30 Days)
- COGT 2.4M
- SBLK 841.2K
- Earning Date
- COGT 10-31-2025
- SBLK 11-18-2025
- Dividend Yield
- COGT N/A
- SBLK 1.06%
- EPS Growth
- COGT N/A
- SBLK N/A
- EPS
- COGT N/A
- SBLK 1.05
- Revenue
- COGT N/A
- SBLK $1,131,251,000.00
- Revenue This Year
- COGT N/A
- SBLK N/A
- Revenue Next Year
- COGT N/A
- SBLK $19.06
- P/E Ratio
- COGT N/A
- SBLK $17.88
- Revenue Growth
- COGT N/A
- SBLK 2.95
- 52 Week Low
- COGT $3.72
- SBLK $12.06
- 52 Week High
- COGT $17.15
- SBLK $20.54
- Technical
- Relative Strength Index (RSI)
- COGT 61.29
- SBLK 60.37
- Support Level
- COGT $14.20
- SBLK $17.47
- Resistance Level
- COGT $16.50
- SBLK $17.98
- Average True Range (ATR)
- COGT 0.84
- SBLK 0.40
- MACD
- COGT -0.07
- SBLK 0.19
- Stochastic Oscillator
- COGT 71.19
- SBLK 96.12
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.